证券代码：603639 证券简称：海利尔 公告编号：2024-001 海利尔药业集团股份有限公司 关于股权激励限制性股票回购注销实施的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购注销原因：根据公司 2021 年限制性股票激励计划相关规定，公司部 分激励对象已不符合激励条件，公司拟对该激励对象已获授但尚未解锁的限制性 股票进行回购注销。 本次注销股份的有关情况： | 回购股份数量 | 注销股份数量 | | 注销日期 | | | | --- | --- | --- | --- | --- | --- | | 224,350 股 | 224,350 | 股 | 2024 1 月 | 年 | 5 日 | 一、本次限制性股票回购注销的决策与信息披露 （三）回购注销安排 根据公司 2021 年第一次临时股东大会的授权，2023 年 10 月 27 日，公司召 开第五届董事会第二次会议和第五届监事会第二次会议，审议通过《关于回购注 销部分激励对象已获授但尚未解锁的限制性股票的议案》。公司部分激励对象已 不再满足 ...

证券代码：603639 证券简称：海利尔 公告编号：2023-058 海利尔药业集团股份有限公司 关于持股 5%以上股东及董事、高级管理人员集中竞价 减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 大股东及董事、高级管理人员持股的基本情况 本次减持计划实施前，海利尔药业集团股份有限公司（以下简称"公司"） 股东青岛合意投资中心（有限合伙）持有公司股份 17,849,951 股，占公司总股 本的 5.2464%；原董事李建国先生持有公司股份 144,480 股，占公司总股本的 0.0425%；董事、高级管理人员刘玉龙先生持有公司股份 193,640 股，占公司总 股本的 0.0569%；高级管理人员迟明明女士持有公司股份 14,200 股，占公司总 股本的 0.0042%。 集中竞价减持计划的实施结果情况 公司于 2023 年 4 月 28 日披露了《关于持股 5%以上股东及董事、高级管理 人员集中竞价减持股份计划公告》（公告编号：2023-026）。截止本公告披露日， 本次减持计划时 ...

Group 1: Meeting Details - The meeting is scheduled for November 8, 2023, from 15:00 to 17:00 [3] - The meeting will be held online via the "Panorama Roadshow" website [3] - Investors can participate through the "Panorama Roadshow" website, WeChat public account, or by downloading the Panorama Roadshow APP [4] Group 2: Purpose of the Meeting - The meeting aims to provide a comprehensive understanding of the company's Q3 2023 performance and financial status [2] - Topics of discussion will include corporate governance, development strategy, operational status, financing plans, equity incentives, and sustainable development [2] Group 3: Participants - Key participants include Chairman and General Manager Ge Jiacheng, Financial Director Liu Yulong, Secretary of the Board Chi Mingming, and Independent Director Yang Aiyi [4] Group 4: Contact Information - Contact person for inquiries is Chi Mingming, reachable at phone number 0532-58659169 and email hailir@hailir.cn [4] Group 5: Additional Information - After the meeting, investors can view the meeting's proceedings and key content on the "Panorama Roadshow" website [5]

Major Financial Data [Major Accounting Data and Financial Indicators](index=1&type=section&id=Major%20Accounting%20Data%20and%20Financial%20Indicators) The company's Q3 2023 operating revenue grew 5.25% and net profit attributable to parent company shareholders increased 9.96%, with year-to-date operating cash flow up 90.99% Key Financial Indicators for Q3 and YTD 2023 | Indicator | Current Reporting Period (Q3) | Year-to-Date (YTD) | Year-over-Year Change (YTD) (%) | | :--- | :--- | :--- | :--- | | Operating Revenue (CNY) | 1,044,000,000 | 3,707,000,000 | -2.51% | | Net Profit Attributable to Shareholders of the Listed Company (CNY) | 111,000,000 | 442,000,000 | 2.70% | | Net Profit Attributable to Shareholders of the Listed Company (Excluding Non-Recurring Items) (CNY) | 98,000,000 | 476,000,000 | -1.42% | | Net Cash Flow from Operating Activities (CNY) | Not Applicable | 579,000,000 | 90.99% | | Basic Earnings Per Share (CNY/share) | 0.33 | 1.30 | 3.13% | | Total Assets (Period-End) (CNY) | 6,401,000,000 | 6,401,000,000 | 9.65% (compared to previous year-end) | | Shareholders' Equity Attributable to Shareholders of the Listed Company (Period-End) (CNY) | 3,351,000,000 | 3,351,000,000 | 4.33% (compared to previous year-end) | [Non-Recurring Gains and Losses Items and Amounts](index=2&type=section&id=Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) During Q3 2023, the company's total non-recurring gains and losses amounted to **13.63 million CNY**, primarily from fair value changes of financial assets/liabilities, while year-to-date, the total was **-33.28 million CNY**, mainly due to accumulated fair value losses Major Non-Recurring Gains and Losses Items (Unit: CNY) | Item | Amount for Current Period (CNY) | Amount Year-to-Date (CNY) | | :--- | :--- | :--- | | Gains and Losses from Fair Value Changes | 13,010,220.65 | -39,066,554.87 | | Government Grants Recognized in Current Profit/Loss | 2,022,094.54 | 8,983,666.60 | | Gains and Losses from Disposal of Non-Current Assets | -1,473,532.82 | -1,948,164.86 | | **Total** | **13,634,591.44** | **-33,281,067.17** | [Changes and Reasons for Major Accounting Data and Financial Indicators](index=4&type=section&id=Changes%20and%20Reasons%20for%20Major%20Accounting%20Data%20and%20Financial%20Indicators) Significant period-end changes include a 60.21% increase in accounts receivable, a 161.43% rise in construction in progress, a 93.87% decrease in financial expenses, and a 90.99% growth in net cash flow from operating activities Changes and Reasons for Major Financial Indicators | Item | Change (%) | Primary Reason | | :--- | :--- | :--- | | Accounts Receivable | 60.21 | Shipments during peak sales season not yet due for payment | | Construction in Progress | 161.43 | Increased investment in Hengning Project | | Financial Expenses | -93.87 | Impact of exchange rate fluctuations | | Net Cash Flow from Operating Activities | 90.99 | Timely collection of sales proceeds | Shareholder Information [Shareholder Holdings](index=5&type=section&id=Total%20Number%20of%20Common%20Shareholders%2C%20Preferred%20Shareholders%20with%20Restored%20Voting%20Rights%2C%20and%20Top%20Ten%20Shareholders%27%20Holdings) As of the period-end, the company had 13,469 common shareholders, with the top three shareholders, Zhang Aiying, Ge Yaolun, and Ge Jiacheng, acting in concert and collectively holding over 59% of shares, indicating a relatively concentrated equity structure - As of the period-end, the company had **13,469** common shareholders[13](index=13&type=chunk) Top Three Shareholders' Holdings | Shareholder Name | Holding Percentage (%) | Related Party Relationship | | :--- | :--- | :--- | | Zhang Aiying | 37.40 | Concerted Action Party | | Ge Yaolun | 18.23 | Concerted Action Party | | Ge Jiacheng | 3.74 | Concerted Action Party | Other Reminders [Other Important Operating Information Requiring Investor Attention](index=6&type=section&id=Other%20Important%20Operating%20Information%20Requiring%20Investor%20Attention) The company has no other significant operating information requiring special investor attention during the current reporting period - The company has no other significant operating information requiring special investor attention during the current reporting period[15](index=15&type=chunk) Quarterly Financial Statements [Type of Audit Opinion](index=6&type=section&id=Type%20of%20Audit%20Opinion) The financial statements for this quarter are unaudited - The company's Q3 2023 financial statements are unaudited[15](index=15&type=chunk) [Financial Statements](index=6&type=section&id=Financial%20Statements) This section presents the company's consolidated balance sheet as of September 30, 2023, and the consolidated income statement and cash flow statement for January-September 2023 [Consolidated Balance Sheet](index=6&type=section&id=Consolidated%20Balance%20Sheet) As of September 30, 2023, the company's total assets were **6.401 billion CNY**, up 9.65% from year-end; total liabilities were **3.050 billion CNY**, up 16.17%; and shareholders' equity attributable to listed company shareholders was **3.351 billion CNY**, up 4.33%, with an asset-liability ratio of 47.65% Key Balance Sheet Items (As of September 30, 2023) | Item | Sep 30, 2023 (CNY) | Dec 31, 2022 (CNY) | Change (%) | | :--- | :--- | :--- | :--- | | Total Assets | 6,401,025,895.36 | 5,837,602,158.84 | 9.65 | | Total Liabilities | 3,050,076,804.11 | 2,625,649,238.99 | 16.17 | | Shareholders' Equity Attributable to Shareholders of the Listed Company | 3,350,949,091.25 | 3,211,952,919.85 | 4.33 | - Asset growth primarily stemmed from **accounts receivable (+60.21%)** and **construction in progress (+161.43%)**, while liability growth was mainly driven by short-term borrowings, notes payable, and taxes payable[10](index=10&type=chunk)[16](index=16&type=chunk)[17](index=17&type=chunk) [Consolidated Income Statement](index=9&type=section&id=Consolidated%20Income%20Statement) For the first three quarters of 2023, the company reported total operating revenue of **3.707 billion CNY**, a 2.51% year-over-year decrease, and net profit attributable to parent company shareholders of **442 million CNY**, a 2.70% increase, driven by effective control over operating costs and financial expenses, alongside a 20.67% rise in R&D expenses Key Income Statement Items (First Three Quarters of 2023) | Item | First Three Quarters of 2023 (CNY) | First Three Quarters of 2022 (CNY) | Year-over-Year Change (%) | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 3,707,271,408.11 | 3,802,550,062.12 | -2.51 | | Total Operating Costs | 3,097,495,540.35 | 3,180,955,439.46 | -2.62 | | Net Profit Attributable to Parent Company Shareholders | 442,221,155.56 | 430,591,861.86 | 2.70 | | Basic Earnings Per Share (CNY/share) | 1.30 | 1.26 | 3.17 | - Research and development expenses increased **20.67%** year-over-year to **193 million CNY**, while financial expenses shifted from **-99 million CNY** in the prior year to **-6 million CNY** due to exchange rate fluctuations[20](index=20&type=chunk) [Consolidated Cash Flow Statement](index=11&type=section&id=Consolidated%20Cash%20Flow%20Statement) In the first three quarters of 2023, net cash flow from operating activities significantly increased by **90.99%** to **579 million CNY**, primarily due to timely collection of sales proceeds and reduced procurement outlays, while net cash outflows from investing and financing activities were **544 million CNY** and **94 million CNY**, respectively, resulting in a period-end cash and cash equivalents balance of **281 million CNY** Key Cash Flow Statement Items (First Three Quarters of 2023) | Item | First Three Quarters of 2023 (CNY) | First Three Quarters of 2022 (CNY) | Year-over-Year Change (%) | | :--- | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 579,122,250.94 | 303,218,727.76 | 90.99 | | Net Cash Flow from Investing Activities | -544,011,574.81 | -555,269,883.47 | Not Applicable | | Net Cash Flow from Financing Activities | -94,288,754.00 | 327,499,464.15 | Not Applicable | | Cash and Cash Equivalents at Period End | 280,678,286.82 | 605,750,856.27 | -53.68 | - The strong growth in operating cash flow was primarily driven by a **15.52%** year-over-year decrease in cash paid for goods and services, while cash received from sales of goods and services remained largely stable[25](index=25&type=chunk)[26](index=26&type=chunk)

证券代码：603639 证券简称：海利尔 公告编号：2023-056 除上述条款外，《公司章程》其他条款内容不变，最终以工商部门核准备案 为准。 上述修订《公司章程》及相应注册资本变更办理工商变更登记的事项已经公 司 2023 年第一次临时股东大会授权，无需再次提交公司股东大会审议。 海利尔药业集团股份有限公司 关于修改公司章程的公告 修 订 后 的 全 文 请 见 公 司 于 2023 年 10 月 28 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的《公司章程》。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 特此公告。 海利尔药业集团股份有限公司（以下简称"公司"）于 2023 年 10 月 27 日 召开了第五届董事会第二次会议，审议通过了《关于修改公司章程的议案》。同 意公司减少注册资本，并对《公司章程》进行修订。具体情况如下： 海利尔药业集团股份有限公司董事会 鉴于公司2021年限制性股票激励计划31名激励对象因离职已不符合激励条 件，其持有的已获授但未解锁部分限制性股票共 2 ...

（本页以下无正文） 海利尔药业集团股份有限公司独立董事关于 第五届董事会第二次会议有关事项的独立意见 根据《公司法》《公司章程》和《海利尔药业集团股份有限公司独立董事 工作制度》的规定，作为海利尔药业集团股份有限公司（以下简称"公司"）的 独立董事，本着认真、负责的态度，我们对公司本次会议相关事项进行了充分 的审查。经认真审阅文件后，基于我们的独立判断，现就相关事项发表如下独 立意见： 一、关于回购注销部分激励对象已获授但尚未解锁的限制性股票的独立意 见 公司本次回购注销部分限制性股票符合《上市公司股权激励管理办法》、公 司《激励计划》及相关法律法规的规定，审议程序合法合规。公司将于本次回 购完成后依法履行相应的减资程序。公司本次回购注销导致的注册资本减少不 会对公司的正常生产经营产生重大影响。不存在损害全体股东尤其是中小股东 利益的情形。 综上，我们一致同意公司本次回购注销部分限制性股票事宜。 （此页无正文，为海利尔药业集团股份有限公司独立董事关于第五届董事会第 二次会议有关事项的独立意见签字页） 独立董事签字： （此页无正文，为海利尔药业集团股份有限公司独立董事关于第五届董事会第 二次会议有关事项的独立意 ...

证券代码：603639 证券简称：海利尔 公告编号：2023-050 海利尔药业集团股份有限公司 关于公司第五届董事会第二次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 具体内容详见公司于 2023 年 10 月 28 日在《上海证券报》及上海证券交易所网 站（www.sse.com.cn）披露的《关于公司 2023 年三季度主要经营数据的公告》（公 告编号 2023-053）。 表决结果：同意票 9 票，反对票 0 票，弃权票 0 票。 3、审议通过《关于回购注销部分激励对象已获授但尚未解锁的限制性股票的 海利尔药业集团股份有限公司(以下简称"公司")第五届董事会第二次会议于 2023 年 10 月 27 日以通讯表决的方式召开。会议通知于 2023 年 10 月 24 日以电子 邮件发出，会议应到董事 9 名，实到董事 9 名，公司监事会人员、高级管理人员列 席了会议，符合《中华人民共和国公司法》和《海利尔药业集团股份有限公司章程》 的有关规定，会议合法有效。 二、董事会会议审议情 ...

证券代码：603639 证券简称：海利尔 公告编号：2023-054 海利尔药业集团股份有限公司 关于回购注销部分激励对象已获授但尚未解锁的限制性股 票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 海利尔药业集团股份有限公司（以下简称"公司"）于 2023 年 10 月 27 日 召开第五届董事会第二次会议，审议通过了《关于回购注销部分激励对象已获授 但尚未解锁的限制性股票的议案》，根据公司《2021 年限制性股票激励计划（草 案）》相关规定，公司有 31 名激励对象因离职已不符合激励条件，公司将对该 激励对象已获授但尚未解锁的 22.435 万股限制性股票进行回购注销。公司已于 2021 年 3 月 23 日召开 2021 年第一次临时股东大会审议通过了《关于提请股东 大会授权董事会办理股权激励相关事宜的议案》，故本次回购注销无需提交股东 大会审议。现将相关事项公告如下： 一、本次激励计划已履行的相关审批程序和信息披露情况 1、2021 年 3 月 5 日，公司召开第四届董事会第三次会议和第四届监事会第 三次会议， ...

海利尔药业集团股份有限公司 2023 年三季度主要经营数据公告 证券代码：603639 证券简称：海利尔 公告编号：2023-053 三、主要原材料的价格变动情况（不含税） | 主要产品 | 2023 9 | 年 | 1 | 至 | 月 | 2022 9 | 年 | 1 | 至 | 月 | 变动比 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 平均进价（万元/吨） | | | | | 平均进价（万元/吨） | | | | | 率（%） | | 丙烯腈 | | | | | 0.79 | | | | | 0.98 | -19.68 | | 二甲基甲酰胺(DMF) | | | | | 0.46 | | | | | 1.14 | -59.23 | | 甲苯 | | | | | 0.65 | | | | | 0.69 | -5.58 | | 一甲胺精品 | 0.57 | 1.54 | -63.25 | | --- | --- | --- | --- | | 液氯 | 0.02 | 0.06 | -63.31 ...